Dr. Arfè’s research interests include statistical decision theory, Bayesian analysis, and reinforcement learning. Dr. Arfè collaborates with investigators in the Genito-Urinary Oncology Service and with members of the MSK Biomarker Development Program to study new blood-based biomarkers in metastatic Castrate-Resistant Prostate Cancer (mCRPC) based on circulating tumor cells. He is also collaborating with investigators in the MSK Department of Radiation Oncology to design a clinical trial of post-operative brachytherapy for early-stage endometrial cancer patients. In his current methodological research, Dr. Arfè aims to develop new adaptive group-sequential clinical trial designs that leverage data from completed studies by means of machine learning methods. In support to his research program, he has been selected to receive Developmental Funds from the Cancer Center Support Grant.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Andrea Arfe discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.